Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
2hon MSN
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback